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In 1992, the National Surgical Adjuvant Breast and Bowel Project
initiated the Breast Cancer Prevention Trial (BCPT-P-1) to deter-
mine whether administering tamoxifen for 5 years prevented inva-
sive breast cancer in women at increased risk for that disease. In a
preliminary report with average follow-up of 4.5 years, tamoxifen
was shown to reduce the overall risk of invasive breast cancer by
49% (Fisher et al, 1998). In October 1998, the United States Food
and Drug Administration (FDA) approved the use of tamoxifen to
‘reduce the incidence of breast cancer in women at high risk’ for
this disease (Zeneca, 1998). A careful examination of the trial’s
results suggests that there were both beneficial and adverse effects
from administering ‘preventive’ tamoxifen.1 Moreover, there were
wide margins of error in the estimates of the beneficial and adverse
effects in the study. Given the debate that has surrounded this
study (Bruzzi, 1998; Pritchard, 1998; Fisher, 1999; Lippman and
Brown 1999; Noe et al, 1999; Radmacher and Simon 2000), it was
considered beneficial to estimate the population health impacts of
preventive tamoxifen on women cared for in the Canadian health
care environment. The objective of our analysis was to identify
under which conditions preventive tamoxifen seemed to provide
an overall benefit to women and also to identify if there were any
situations under which it might be detrimental. 
METHODS 
The Population Health Model (POHEM) 
POHEM is a microanalytic simulation model developed by the
Health Analysis and Modeling Group at Statistics Canada, the
Canadian government’s central statistical agency. 
POHEM creates synthetic longitudinal population samples
starting with the birth of each individual in the cohort, and dynam-
ically simulates their ageing, including exposures to risk factors,
disease onset conditional on risks, treatment, case fatality and
costs (Wolfson, 1994; Berthelot et al, 1997). It does this by synthe-
sizing a large sample of complete individual health and socio-
economic biographies. The synthesis process respects and draws
upon a myriad of detailed empirical observations. To evaluate
tamoxifen, we used a birth cohort and when women met the eligi-
bility criteria they were screened into the simulated therapy. The
simulation sample size typically used in this analysis was 4 million
women, to ensure that the Monte Carlo error was small relative to
the model outputs of interest. 
POHEM has been used successfully to develop a comprehen-
sive model of the lifetime costs of diagnosing and treating 
breast cancer in Canada, to reflect current Canadian risk factors,
incidence, diagnostic and therapeutic cancer management prac-
tices and costs (Will et al, 1999, 2000). Recently, the model 
has been modified to evaluate the health and economic impact of
interventions such as reduced length of in-hospital stay for breast
cancer surgery and post-mastectomy locoregional radiotherapy for
node-positive Stage II breast cancer patients (Will et al, 1998;
Evans et al, 2000). 
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For this analysis, tamoxifen’s impact on breast and endometrial
cancer (BC and EC), deep vein thrombosis (DVT), stroke, coronary
heart disease (CHD), fractures and cataracts has been evaluated. In
addition, mortality from causes other than those listed above was
explicitly modeled, but without any preceding morbidity. A wide
variety of data sources were culled (references are contained in the
original breast cancer reports – Will et al, 1999; Will et al, 2000).
Breast and endometrial cancer incidence data were obtained from
the national cancer registry by age group. Breast cancer risk factors
were taken from the National Breast Screening Study and from
vital statistics records. Baseline incidence for the remaining
diseases under study was calculated from the electronic health care
records maintained by the province of Manitoba. 
Mortality rates for the individual diseases were modelled to
reflect as closely as possible those from Canadian vital statistics
records. No mortality was associated with cataracts or DVT in the
model, but they have still been modeled because their incidence is
significantly affected by tamoxifen. The use of hormone replace-
ment therapy (HRT) is included since it affects whether women are
eligible for tamoxifen. These modules have been validated by
ensuring that the incidence (when known), overall life expectancy,
and disease-specific mortality rates generated by POHEM corre-
spond to those observed in Canada. See Appendix A for details on
the diseases in the model and the methodology used. 
Assumptions in modeling preventive tamoxifen for
Canadian women 
POHEM was used to simulate the administration of preventive
tamoxifen to a representative cohort of Canadian women. The
reference case assumed no provision of preventive tamoxifen. The
main intervention scenario (Scenario 1) conformed as closely as
possible to the eligibility criteria for tamoxifen in the BCPT-P-1
protocol. Women were defined to be at increased risk for breast
cancer in the simulation if they: 
  were 60 to 702 years of age; or 
  were 35–59 years of age with a 5-year predicted risk of breast
cancer of at least 1.66%; or 
  had a history of lobular carcinoma in situ (LCIS); 
  had no history of deep vein thrombosis or endometrial cancer;
and 
  had not taken hormone replacement therapy in the 3 months
prior to starting on tamoxifen. 
Estimating the 5-year predicted risk 
For this analysis, we used the Gail algorithm for estimating the
probability (risk) of breast cancer over time (Gail et al, 1999) in the
same way as in the BCPT-P-1 to predict each simulated woman’s 5-
year risk of breast cancer. POHEM’s simulated individual risk
profiles, in aggregate, replicate Canadian risk factor distributions
for age, family history, nulliparity or age at first live birth, number
of breast biopsies, and age at menarche. For each synthetic woman,
the odds ratios from Gail et al were used in combination with the
age-specific Canadian breast cancer incidence rates to estimate the
5-year predicted risk. If this predicted risk was high enough to
place the woman in the eligible range, the intervention simulated
was 20 mg of tamoxifen per day for 5 years. Tamoxifen administra-
tion was assumed to have been stopped at the onset of deep vein
thrombosis, breast cancer, or endometrial cancer. 
Incorporating all outcomes from the BCPT-P-1 
When the results of a clinical trial are reported, much emphasis is
put on the primary endpoint for which it was designed. In the case
of preventive tamoxifen, the highlight of the trial was the 49%
reduction in breast cancer incidence. However, other outcomes
were measured (e.g., endometrial cancer, deep vein thrombosis,
etc.) with varying degrees of precision. In performing an evalua-
tion of the global impact of an intervention, many researchers use
the point estimates of the different outcomes. However, since
some outcomes are not statistically significant, or are of borderline
statistical significance, some judgement is required as to which are
likely to be real. This means that different researchers could arrive
at different conclusions regarding which outcomes to include.
Instead of using the point estimates of the relative risks (which
would force a subjective decision about which of the relative risks
are significant), we used the entire information on their distribu-
tion, as published from the BCPT-P-1. 
Table 1 summarizes the relative risks (RRs) of developing
certain diseases, and their confidence intervals, as derived from
the BCPT-P-1. Our approach is to perform a multivariate analysis
that takes into account parametric uncertainty based on the distrib-
ution of the input parameters. POHEM draws from the distribution
of the input parameters and associates distinct parameter values to
different sub-samples. For this analysis, 40 sub-samples were
used. Effectively, this is similar to conducting ‘pseudo-trials’ that
would have resulted in point estimates within the confidence
interval for each of the outcomes under study. The variation
between sub-samples is used to calculate standard errors for the
simulation results. In this manner, the multivariate distribution of
the outcomes can be estimated and parametric uncertainty can be
incorporated into the simulation run. Furthermore, using the infor-
mation from the distributions allows for the calculation of standard
errors that reflect the uncertainties of the outcome. For example, if
a relative risk has a very wide confidence interval (i.e. its effect is
highly uncertain), it will not have any significant impact on the
final results. Using the approach of ‘pseudo-trials’ allows us to
keep the information on all outcomes measured in the trial without
having to make subjective decisions. 
The long-term effects of tamoxifen 
Since the median follow-up period in the BCPT-P-1 trial was less
than 5 years, the longer-term consequences of tamoxifen use in
women without breast cancer are not known. It was assumed that
the relative risks (RRs) for breast and endometrial cancer and frac-
tures would return (linearly) to 1.0 within 5 years following cessa-
tion of therapy. It was also assumed that the RRs of coronary heart
disease would return to 1.0, one year after cessation of therapy. For
the other outcomes, it was assumed that the RRs would return to
1.0 immediately after cessation of therapy, as some of the biolog-
ical effects of tamoxifen are thought to be promptly reversed on
cessation of the drug. 
2Even though the trial did not specify a maximum eligibility age, we assumed that, in
the Canadian context, it would be questionable to offer preventive tamoxifen to
women over age 70. This is the only criterion that differs from those in the BCPT-P-1. Reference case and new scenarios 
The reference case assumes that no tamoxifen was administered.
Scenario 1 simulates the BCPT-P-1. Since tamoxifen is not admin-
istered without the potential for harmful side effects, 3 additional
scenarios were simulated in order to evaluate the effectiveness of
preventive tamoxifen on different sub-populations. The second
scenario used more conservative eligibility criteria. It was
assumed that women were at high risk if they were 35 to 70 years
of age with a 5-year predicted risk of ≥ 1.66%, as calculated by the
Gail model. The last two scenarios assumed an even more
restricted population of women for preventive tamoxifen.
Tamoxifen was administered in these scenarios if the woman was
between 35 and 70 and had a 5-year predicted risk of breast cancer
of at least 3.32% (twice the eligibility criteria of BCPT-P-1), and
4.15%, respectively. A range of additional scenarios has been
modelled (≥ 2.08%,  ≥ 2.49%,  ≥ 2.91%,  ≥ 3.74%), but is not
presented. The results are available on request. 
Sensitivity analyses 
Sensitivity analyses are used to determine the impact on the results
of changes to one or more parameter assumptions in the analysis.
If the conclusions drawn from a simulation model are not affected
by such sensitivity analyses, it can be assumed that the conclusions
are robust with regard to the assumptions examined. 
One sensitivity analysis explored the impact of a longer dura-
tion of the protective effects of tamoxifen for cancer after cessa-
tion of therapy, tailing off over a 10-year, rather than a 5-year
period. In this sensitivity analysis, we also determined the impact
of alternatively assuming that the RRs of cancers and fractures
would return (linearly) to 1.0 within 10 (rather than 5) years
following cessation of therapy. A second analysis retained the
baseline assumption of a 5-year tailing off of protective effects of
tamoxifen, but instead, assumed that tamoxifen had a beneficial
effect on mortality from cancers other than breast and endometrial
(RR of 0.57), and a detrimental effect on all other causes of death
(RR of 1.21), as inferred from Table 11 of the BCPT-P-1 study
report. 
In this latter case, our analysis of the detailed counts of deaths
by cause suggests a statistically significant beneficial effect on
‘other cancer’ mortality (i.e. excluding breast and endometrial
cancer), even though the published results showed no significant
difference in overall mortality between the placebo and tamoxifen
arms of the trial, and the study found no significant difference in
‘other cancer’ incidence between the 2 arms. This result appeared
paradoxical to us. These effects on mortality by cause may be due
to the relatively small numbers of events and the short follow-up
time for mortality effects. Nonetheless, a sensitivity analysis was
performed to determine if the published reduction in other cancer
mortality and increase in other non-cancer mortality might have an
impact on the overall results. 
RESULTS 
Since each POHEM scenario covers a different population with a
different underlying risk of breast cancer and other diseases, the
reference for each scenario is provided in Table 2. Table 3 provides
the changes observed between each ‘reference case without
tamoxifen’ and the preventive tamoxifen scenario. Table 4
presents the sensitivity analyses of the results to alternative
assumptions regarding the long-term effects of tamoxifen. 
In the reference case (Scenario 1 in Table 2), life expectancy for
eligible Canadian women in 1991 was 83.9 years, and 67.8% of all
women could expect to survive to age 80. Almost 9% could expect
to have breast cancer at some point in their lives, and to spend
almost 11 years living with the disease, and 3.2% could expect to
die from breast cancer. 
When we look cross-sectionally at women in the year 2000,
using BCPT-P-1 eligibility criteria, 23% of the Canadian popula-
tion would be eligible for tamoxifen. However, from a population
health perspective, it is also important to look at the lifetime poten-
tial of being eligible for this drug. Overall, applying the BCPT-P-1
eligibility criteria to Canadian women (Scenario 1 in Table 2)
would result in over 85% of all women being subjected to tamox-
ifen administration at some point in their lives. These women
taking tamoxifen could anticipate a significant decrease (P < 0.05)
in life expectancy of about 0.04 years, while the proportion
surviving to age 80 would decrease by about 0.2%. The burden of
breast cancer would fall, but the burdens of CHD, endometrial
cancer, stroke, hip fracture and cataracts would all increase.
Mortality from other diseases in the simulation would also fall.
These simulation results suggest that preventive tamoxifen may
not be beneficial to the health of Canadian women when offered
according to the eligibility criteria of BCPT-P-1. 
To determine if tamoxifen might be beneficial to various subsets
of women at higher risk of breast cancer, several alternatives were
1282 BP Will et al 
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Table 1 Summary of results of the BCPT-P1 
Disease incidence Age group RR (CI) 
Breast cancer 35–49 0.56 (0.37, 0.85) 
50–59 0.49 (0.29, 0.81) 
60+ 0.45 (0.27, 0.74) 
Endometrial cancer 35–49 1.21 (0.41, 3.60) 
50+ 4.01 (1.70, 10.90) 
Coronary heart disease All 1.15 (0.81,  1.64) 
Hip fractures All 0.55 (0.25,  1.15) 
Spine fractures* All 0.74 (0.41,  1.32) 
Wrist fractures* All 0.93 (0.69,  1.27) 
Stroke 35–49 0.76 (0.11, 4.49) 
50+ 1.75 (0.98, 3.20) 
Deep vein thrombosis* 35–49 1.39 (0.51, 3.99) 
50+ 1.71 (0.85, 3.58) 
Cataract onset* All 1.14 (1.01,  1.29) 
Cataract surgically treated* All 1.57 (1.16,  2.14) 
Mortality 
Other Cancer Mortality** All 0.57 (0.31, 0.97) 
Other Non-Cancer Mortality** All 1.21 (0.69, 2.22) 
RR = relative risk; Cl = confidence intervals. 
*assumed non-fatal. 
**RR for mortality is assumed to be 1 in base scenarios. 
***RRs and Cls are from Tables 3, 4, 6, 7, 8, 9 and 11 of Fisher et al (1998)
reference. 
Note: 
The RR for ‘Other Cancer Mortality’ is the ratio of the number of deaths due
to cancer (excluding breast and endometrial) in the intervention group
divided by the number of person-years of follow-up for the intervention group
over the same quantity from the control group. Source: Table 11 of Fisher 
et al (1998) reference. 
The RR for ‘Other Non-Cancer Mortality’ is the ratio of the number of deaths
due to causes other than cancer, coronary heart disease, hip fracture or
stroke in the intervention group divided by the number of person-years of
follow-up for the intervention group over the same quantity from the control
group. Source: Table 11 of Fisher et al (1998) reference. simulated. In the first alternative, eligibility for tamoxifen after age
60 was made more stringent by requiring a 5-year predicted risk of
at least 1.66% for all women 35 to 70 years of age. The baseline
characteristics and the results of this simulation are shown as
Scenario 2 in Tables 2 and 3, respectively. Under this scenario,
42% of women would be eligible for preventive tamoxifen at some
point in their lives. This population would have a higher risk of
breast cancer than that in the first scenario. For this subpopulation,
there would be a decrease in life expectancy of 0.01 years, which
is not statistically significant. In this simulation, the increases in
mortality from CHD, endometrial cancer, stroke and hip fracture
would counterbalance any benefit of tamoxifen in reducing breast
cancer mortality. 
Scenario 3 shows the impact of preventive tamoxifen therapy
for women aged 35 to 70, who, based on the Gail algorithm, would
have a 5-year predicted risk of breast cancer of 3.32%. For this
First do no harm: Extending the debate on preventive tamoxifen 1283
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Table 2 Base case outcomes for each scenario 
Eligibility criteria Scenario 1 Scenario 2 Scenario 3 Scenario 4 
BCPT-P-1 5-year BC 5-year BC 5-year BC 
risk ≥ 1.66, risk ≥ 3.32, risk ≥ 4.15, 
age 35–70 age 35–70 age 35–70 
Lifetime percentage of women eligible 85.1 42.3 4.0 1.7 
Life expectancy (years) 83.9 83.9 84.3 84.4 
Percentage alive at age 80 67.8 68.0 69.2 69.2 
BC Incidence (%) 8.7 11.1 16.4 18.6 
BC Mortality (%) 3.2 4.1 5.9 6.5 
Average person-years with BC 10.4 10.8 10.1 9.8 
CHD incidence (%) 49.2 48.5 47.1 46.9 
CHD mortality (%) 23.3 23.1 22.9 22.9 
EC incidence (%) 1.8 1.8 1.6 1.5 
EC mortality (%) 0.5 0.4 0.4 0.4 
Stroke incidence (%) 32.7 32.5 32.5 32.3 
Stroke mortality (%) 7.9 7.9 8.0 7.9 
Hip fracture incidence (%) 18.9 18.8 18.5 18.5 
Hip fracture mortality (%) 3.3 3.3 3.4 3.4 
Cataract incidence (%) 30.8 29.7 28.3 27.9 
Other cancer mortality (%) 13.7 13.5 12.8 12.6 
Other cause mortality (%) 44.6 44.4 43.7 43.5 
BC = breast cancer; EC = endometrial cancer; CHD = coronary heart disease. 
Table 3 Impacts of alternative scenarios for administering tamoxifen 
Change under alternative scenarios 
Eligibility criteria for each scenario Scenario 1 Scenario 2 Scenario 3 Scenario 4 
Similar to BCPT-P-1 5-year BC 5-year BC 5-year BC 
risk ≥ 1.66, risk ≥ 3.32, risk ≥ 4.15, 
age 35–70 age 35–70 age 35–70 
Life expectancy (LE) (years) –0.04 –0.01NS 0.06 0.07 
Probability of increase in LE (%) 30.0 43.0 75.0 75.0 
Percentage alive at age 80 –0.2 –0.1NS 0.2 0.4 
BC incidence (%) –1.2 –1.4 –2.5 –3.1 
BC mortality (%) –0.5 –0.7 –1.1 –1.3 
Average person–years with BC –0.69 –0.6 –0.60 –0.69 
CHD incidence (%) 0.3 0.4 0.7 0.8 
CHD mortality (%) 0.2 0.2 0.3 0.5 
EC incidence (%) 1.4 1.4 1.5 1.6 
EC mortality (%) 0.4 0.4 0.4 0.4 
Stroke incidence (%) 0.2 0.4 0.9 0.9 
Stroke mortality (%) 0.1 0.1 0.2 0.3 
Hip fracture incidence (%) 0.3 0.1NS –0.1NS –0.5 
Hip fracture mortality (%) 0.1 0.0NS –0.1NS –0.1 
Cataract incidence (%) 0.3 0.4 0.7 0.6 
Other cancer mortality (%) 0.0NS 0.0NS 0.0NS 0.0NS
Other cause mortality (%) –0.1 0.0NS 0.2 0.2 
Note: The changes are relative to the appropriate reference column in Table 2. 
BC = breast cancer; EC = endometrial cancer; CHD = coronary heart disease. 
NS = Not significant at P ≤ 0.05 (otherwise, the change is significant). 1284 BP Will et al 
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sub-population, there would be a significant increase (P < 0.05) in
life expectancy of 0.06 years, and a 0.2% increase in the propor-
tion reaching age 80. 
Finally, Scenario 4 shows the results of administering tamoxifen
to the 1.7% of the population of women whose risk of breast
cancer would, at some point in their life course, be 2 1/2 times
higher than that in the BCPT-P-1, at 4.15%. This scenario esti-
mates a significant increase (P < 0.05) in life expectancy of 0.07
years. For this population, there would be a marked decrease
(3.1%), in the incidence of breast cancer and a decrease of 0.7
years with breast cancer for this sub-population. 
Table 4 shows the results of 2 sensitivity analyses, juxtaposed
against the ‘standard’ BCPT-P-1 intervention scenario (Scenario
1). The first of these analyses explores the impact of a longer dura-
tion of anti-cancer protective effects from tamoxifen, with the
benefit tailing off over a 10-year, rather than a 5-year period. Even
when it is assumed that the effects of tamoxifen last over a 10-year
period following cessation of therapy, the life expectancy of
women would not increase. The results are consequently not sensi-
tive to this assumption. The second analysis retains the baseline
assumption of a 5-year tailing off of the protective effects of
tamoxifen, but assumes that tamoxifen has a beneficial effect on
mortality from cancers other than breast and endometrial (RR of
0.57), and a detrimental effect on all other causes of death (RR of
1.21). The simulation results indicate an increase in life
expectancy of 0.13 years accompanied by an increase in the
proportion reaching age 80. In this scenario, the probability of an
increase in life expectancy was estimated to be 60%. When
compared to the reference case scenario, it can be seen that the
results of the simulation are highly sensitive to the assumption that
there is no reduction in other cancer mortality. 
DISCUSSION 
Tamoxifen has been used as an adjuvant therapy for metastatic
breast cancer and to decrease the incidence of contralateral 
breast cancer for over 2 decades (Jordan, 1990, 1995; Love et al,
1991; Early Breast Cancer Trialists’ Collaborative Group, 1992;
Tomas et al, 1995; Fisher et al, 1996; Early Breast Cancer
Trialists’ Collaborative Group, 1998). This has created consider-
able debate (Bruzzi, 1998; Pritchard, 1998; Fisher, 1999; Lippman
and Brown 1999; Noe et al, 1999; Radmacher and Simon, 2000),
particularly regarding issues such as impact on cardiovascular
disease (Love et al, 1991), duration of administration (Jordan,
1990; Fisher et al, 1996) and quality of life (Day et al, 1999).
However, there is a general consensus that, for breast cancer
patients, the survival benefits of tamoxifen far outweigh the
adverse effects (Jordan, 1990; Early Breast Cancer Trialists’
Collaborative Group, 1998). 
More recently, attention has been focused on tamoxifen’s poten-
tial to prevent breast cancer in ‘high risk’ women. The release of
the findings of the Breast Cancer Prevention Trial (BCPT-P-1) in
March 1998 resulted in unprecedented media coverage and precip-
itated additional debate regarding the risks and benefits of tamox-
ifen administration. The trial showed a 49% reduction in breast
cancer, but also showed that there were some life-threatening
adverse effects associated with tamoxifen administration (Gail 
et al, 1999). Adding to the debate were the results of two European
tamoxifen chemoprevention trials, which were unable to confirm
the P-1 trial findings, but which also used different sample sizes
and eligibility criteria (Powles et al, 1998; Veronesi et al, 1998). 
One of the major issues concerning the BCPT-P-1 results is that
the trial population has not been followed long enough to produce
Table 4 Sensitivity analysis of estimated impacts of tamoxifen for alternative risk scenarios 
BCPT-P1 10 year return to Other cancer
baseline risks mortality RR = 0.57,
after stopping Other non-cancer
tamoxifen mortality RR = 1.21
Percentage of all women ever
administered tamoxifen  85.1 85.1 85.1
Life expectancy (years) –0.04 –0.03 0.13 
Percentage alive at age 80 –0.2 –0.1 0.5 
BC Incidence (%) –1.2 –1.5 –1.1 
BC Mortality (%) –0.5 –0.7 –0.5 
Average person–years with BC –0.69 –0.83 –0.69 
CHD incidence (%) 0.3 0.4 0.7 
CHD mortality (%) 0.2 0.2 0.4 
Endometrial cancer incidence (%) 1.4 1.9 1.5 
Endometrial cancer mortality (%) 0.4 0.6 0.4 
Stroke incidence (%) 0.2 0.2 0.4 
Stroke mortality (%) 0.1 0.1 0.1 
Hip fracture incidence (%) 0.3 0.1NS 0.4 
Hip fracture mortality (%) 0.1 0.0NS 0.1 
Cataract incidence (%) 0.3 0.3 0.6 
Other cancer mortality (%) 0.0NS 0.0NS –0.7 
Other cause mortality (%) –0.1 –0.1 0.5 
BC = breast cancer; CHD = coronary heart disease. 
NS = Not significant at P ≤ 0.05 (otherwise, the change is significant). First do no harm: Extending the debate on preventive tamoxifen 1285
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reliable mortality data or to determine the net health benefit to
society of a tamoxifen breast cancer prevention strategy, (Pritchard
(1998) and Lippman and Brown (1999)) (See April 19, 2000 JNCI
for comments / critiques by Rockhill et al, and responses by
Lippman and Brown, and by Fisher). 
Gail and his colleagues have developed a methodology to deter-
mine the population of women most likely to benefit from preven-
tive tamoxifen (Gail et al, 1999), and the FDA in the United States
has given approval for the use of tamoxifen for women at
increased risk of breast cancer. However, according to some, there
is still uncertainty as to whether tamoxifen only delays the appear-
ance of breast cancer or truly prevents the disease itself (Zeneca,
1998; Radmacher and Simon, 2000). 
Should all healthy women 60 years of age and older take tamox-
ifen, when only 8.3% are likely to get breast cancer after that age?
Given that the BCPT-P-1 showed a 49% reduction in incidence of
invasive breast cancer for women on the tamoxifen arm, how
many of these have actually been prevented permanently, how
much of the reduction is due to the inhibition of growth of occult
tumours, and what impact will there be on life time breast cancer
mortality? Assuming that there is support for the thesis that tamox-
ifen inhibits the growth and progression of ER-positive tumours,
which are generally found in older women, what proportion of
premenopausal women at high risk would actually benefit from its
administration? There has also been considerable discussion
regarding the importance of evaluating breast cancer risk, as well
as the methodology for doing so (Jordan, 1990; Costantino et al,
1999; Gail et al, 1999; Radmacher and Simon, 2000; Smith and
Hillner, 2000). Finally, concern has been expressed over the ethics
of administering tamoxifen to a healthy population of women and
about the importance of considering its clinical toxicology
(Jordan, 1990, 1995; Emanuel et al, 2000). 
In our model, the eligibility criteria, risk factors and relative
risks from the BCPT-P-1 were applied to a simulated cohort of
Canadian women, using Canadian incidence and mortality rates
and breast cancer management patterns. Besides breast cancer, the
analysis also assessed tamoxifen’s effects on endometrial cancer,
CHD, DVT, stroke, hip fractures, cataracts, and all other causes of
mortality. 
Certain important differences between our analysis and that of
other researchers are relevant. The most important difference is
that the POHEM microsimulation includes life expectancy, and
not just the more proximate end-points of breast cancer incidence
or prevalence (Fisher et al, 1998; Radmacher and Simon, 2000).
We evaluated the lifetime impact and net benefit of providing
preventive tamoxifen to high-risk women for a 5-year period,
whereas others used 5-year risks or effects (Gail et al, 1999; Smith
and Hillner, 2000). Additionally, Noe and colleagues used inci-
dence rates from the trial, rather than the baseline incidence in an
actual population. In our analysis, we considered the overall
impact of all diseases mentioned in the BCPT-P-1 trial, whereas
Noe et al (1999) based their analysis on only those diseases
showing statistically significant differences (breast and endome-
trial cancer, pulmonary embolism and cataract surgery). 
Although Gail et al developed tools to address the harmful risks
of preventive tamoxifen, their risk–benefit analysis was based
upon the number of events. In POHEM, life-years gained or lost
due to these events are also considered. In Gail’s analysis,
endometrial cancer, pulmonary embolism, hip fracture, stroke and
breast cancer were all considered to be of equal weight. By
looking directly at the mortality associated with these events, one
can more accurately assess the impact of these events on lifetime
health. Smith and Hillner (2000) have stated that tamoxifen for
breast cancer prevention should be cost-effective under nearly all
circumstances, but acknowledge that the risk reduction due to
tamoxifen might not result in a reduction in breast cancer deaths.
However, since their analysis did not take into account the life-
years lost due to the harmful side effects of tamoxifen, they may
have over-estimated the benefits of tamoxifen. Furthermore, the
POHEM approach incorporates the uncertainty associated with 
the input parameters as measured by the BCPT-P-1, allowing 
for the calculation of confidence intervals. 
When comparing the results of clinical trials to ‘real-life’ situa-
tions, it is important to distinguish between efficacy and effective-
ness. The BCPT-P-1 trial showed the efficacy of administering
tamoxifen in a clinical trial setting to reduce breast cancer inci-
dence (Fisher et al, 1998). However, practice patterns, tests,
follow-up, and survival within a clinical trial setting are not the
same as in the general population. In order to assess effectiveness,
the setting of the analysis should be the general population, with
standard practice patterns and outcomes. For this reason, in our
POHEM simulation, standard disease progression and mortality
data were used. In the case of endometrial cancer, there were no
deaths in the BCPT-P-1. Although most endometrial cancers might
be prevented with proper screening and tests, in Canada (NCIC),
as in the United States (SEER) (Ries et al, 1997), there is still
mortality associated with this cancer. It has recently been reported
that endometrial cancers discovered in women taking adjuvant
tamoxifen are more advanced at diagnosis and less likely to have a
favourable outcome compared with those in women who have not
taken tamoxifen (Bergman et al, 2000). 
Our study has several limitations. First, the results are based on
hypothetical rather than real cases, and the proportion of cases
receiving specific tests and treatments is based upon the propor-
tion of cases in various categories in the databases used. Survival
data were taken from administrative sources. However, even with
these limitations, the breast cancer model of diagnostic and thera-
peutic procedures and disease progression has been calibrated by
reproducing incidence and overall life expectancy, and approxi-
mating disease-specific mortality, as seen in Canada. 
Few women develop breast cancer in their lifetime. However,
according to the criteria of the BCPT-P-1, 85% of women would
be eligible to take preventive tamoxifen at some point in their
lives. Based on the results of this POHEM simulation, although
tamoxifen has a substantial benefit in reducing breast cancer inci-
dence and mortality, the detrimental effects of tamoxifen on
endometrial cancer, coronary heart disease, stroke, and deep vein
thrombosis may counter-balance the protective effect tamoxifen
has on breast cancer for the majority of the women meeting the
eligibility criteria of BCPT-P-1. As a consequence, the results of
this simulation analysis raise important questions about the use of
preventive tamoxifen. In the United States, tamoxifen is approved
to reduce the incidence of breast cancer in high risk women
who are 35 or older and have a 5-year predicted risk of
≥ 1.67%, as calculated by the Gail model (Gail et al, 1999). 
The results of our simulations are highly sensitive to the
assumption regarding ‘other cancer’ mortality. If it is assumed that
the reduction in mortality for ‘other cancers’ observed in the
BCPT-P-1 is not artefactual, our analysis suggests that preventive
tamoxifen could be effective even for the BCPT-P-1 entry criteria.
However, this mortality reduction is somewhat paradoxical. As
there was no difference in the incidence of other cancers in the twoarms of the trial (RR = 1.0), a reduction in mortality would imply
that tamoxifen had a therapeutic effect on these cancers.
Alternatively the difference could be an artefact of the short
follow-up. 
As a consequence of these uncertainties, additional trials and
longer follow-up of prevention trials would be useful to determine
whether preventive tamoxifen can reduce all-cause mortality, as
well as the more proximate endpoint of breast cancer incidence.
New oestrogen-suppressing drugs, such as raloxifene and anas-
trozele are now being introduced and evaluated, and will require
the same kind of careful evaluation given to tamoxifen. The
ongoing Multiple Outcomes of Raloxifene Evaluation (MORE)
(Cummings et al, 1998) and the Study of Tamoxifen and
Raloxifene (STAR) (National Cancer Institute, 1999) clinical trials
are attempts to find an intervention that will prevent breast cancer
with a minimum of side effects. Overall, the analysis raises ques-
tions about the use of preventive tamoxifen in otherwise healthy
women at high risk of breast cancer. 
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APPENDIX A 
The following paragraphs provide brief overviews of the data
sources and information used to build the major disease modules
in POHEM, including those developed specifically for the analysis
of the impact of preventive tamoxifen on the health of Canadian
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women. For all diseases mentioned below, relative risks (RRs)
from the BCPT-P-1 were applied to the respective incidence rates. 
Breast cancer module 
The sources of data for the POHEM breast cancer module have
previously been described in detail (Will et al, 1999; Will et al,
2000). The breast cancer module starts with age-gender incidence
patterns based on the Canadian Cancer Registry (only female
breast cancer is modeled) (National Cancer Institute of Canada,
1995). For this analysis, the average incidence rates are adjusted
for risk factor exposures, using relative risks from the Gail model.
The risk factors for the breast cancer tamoxifen intervention are
derived from the following sources: the (Canadian) National
Breast Screening Study (NBSS) provided information on family
history of breast cancer, age at menarche and age at menopause
(Miller et al, 1992); Vital Statistics provided data on age of the
mother at the birth of a first child and nulliparity; hormone
replacement therapy (HRT) was derived from health surveys; and
the number of previous breast biopsies was calculated from the
Manitoba electronic database of health care records (Roos et al,
1987; Roos, 1999). 
Since breast cancer survival critically depends on staging, data
on stage at diagnosis were obtained through special arrangements
with provincial cancer registries. The stage distribution used for
the model was Stage I–46%, Stage II–41%, Stage III–7%, and
Stage IV–6%. 
Following diagnosis of initial treatment, breast cancer can
progress along different paths. Based on the stage of the disease at
the time of diagnosis, treatment approaches and follow-up sched-
ules are assigned according to observed proportions, as part of the
Monte-Carlo microsimulation method. For women diagnosed at
Stage I, II or III, three transitions are possible – from diagnosis to
local recurrence, from diagnosis to distant recurrence (or metas-
tasis), or directly from diagnosis to death. 
Once a woman has a local recurrence, transitions to distant
recurrence or to death are possible. Finally, when a woman is diag-
nosed with a distant recurrence (Stage IV), the recurrence is
assigned to one of two sites: visceral or non-visceral. The only
transition allowed at this point is to death, and that transition
occurs at a different pace depending on the site. In general, the
visceral site has a poorer survival. 
Durations between these various discrete events or survival
times have been estimated from detailed longitudinal microdata
obtained from Saskatchewan and Northern Alberta. These
stochastic waiting times are typically represented by piecewise
Weibull distributions. 
Coronary heart disease module 
The progression of coronary heart disease (CHD) is based on
Weinstein et al (1987), with case fatality matching 1991 Canadian
CHD mortality from vital statistics. Incidence of CHD is modeled
as one of four possible events: sudden death, cardiac arrest,
myocardial infarction or angina. Because no national CHD inci-
dence rates are available in Canada, baseline incidence rates are
derived by inverting the Weinstein disease progression model,
working back from 1991 Canadian CHD mortality rates, while
taking account of the underlying risk factor distribution, and
Framingham relative risk functions (from section 37 of the
Framingham reference study) (Abbott, 1987). The major risk
factors for CHD (cholesterol, blood pressure, smoking, age and
gender) are derived from the cross-sectional 1978–1979 Canada
Health Survey, (Health and Welfare Canada, 1981) and are
smoothed using a transport flow analysis to provide the simulation
of longitudinal risk behaviours (Gentleman et al, 1990). 
Hormone replacement therapy (HRT) 
HRT use was one of the eligibility criteria of the BCPT. The inci-
dence of HRT usage has been derived from the cross-sectional
prevalence of HRT in Canada’s 1994 National Population Health
Survey, and a small survey on duration of use conducted by the
University of Ottawa, standardized to the general population of
women. 
The relative risks of hip fracture, CHD and breast cancer are all
affected by HRT. The magnitudes of these effects have been taken
from the Office of Technology Assessment (OTA) study of
Hormone Replacement Therapy (U.S. Congress, 1995) and a liter-
ature review. The risk of CHD is assumed to instantly decrease by
half when HRT is taken and to return to normal levels when HRT
is stopped. 
Hip fracture 
The hip fracture model (Flanagan et al, 1997) is based on the
natural history of bone mineral density (BMD) which has been
extracted from the U.S. Office of Technology Assessment Study of
HRT. Baseline hip fracture rates are derived from the 1986–1990
Manitoba electronic physician and hospitalization records. 
Endometrial cancer 
The Canadian Cancer Registry was used to obtain endometrial
cancer incidence by age groups (National Cancer Institute of
Canada, 1995). Although there was no mortality associated with
endometrial cancer within the BCPT-P-1 trial, the mortality rates
for endometrial cancer and the other individual diseases were
modeled to reflect those from Canadian vital statistics records. 
Stroke 
Electronic health care records from the province of Manitoba were
used to calculate incidence and survival for stroke. The time till
death due to stroke was calculated as a piecewise Weibull func-
tion. 
Cataracts 
Cataracts were also modeled in several stages, using the Manitoba
database referred to above. Once a woman was diagnosed with
cataracts, the time until surgery on the first eye was modeled using
a piecewise Weibull function. The time between the first and
second eye surgery was also modeled based on a Weibull curve. 
Deep vein thrombosis (DVT) 
Incidence of DVT was modeled using information from the
Manitoba database referred to above. No mortality was modeled
for DVT. 1288 BP Will et al 
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Parametric uncertainty 
To reflect parametric uncertainty in our simulation, 40 replicates of
each scenario were simulated. For each replicate, a vector of RRs
was drawn using a Latin hypercube sample design (Ma et al, 1993;
Cronin et al, 1998) from independent lognormal distributions with
the 95% confidence intervals shown in Table 2. Then, 40 cohorts
of 100 000 women each were simulated, based on these 40 vectors
of RRs, for a total of 4 000 000 cases. The variability of several of
the key outcomes was then derived from their distributions over
the 40 replicates. From these sub-populations, the probability of a
positive life expectancy can be estimated empirically. 
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